Loading clinical trials...
Loading clinical trials...
A 3-Month, Open-Label, Pharmacy-Based, Actual-Use Trial in a Simulated Over-The-Counter (OTC) Environment to Assess Self-Selection and Consumer Use Patterns of Gabapentin 250 mg for Occasional Sleeplessness
Conditions
Interventions
Gabapentin
Locations
35
United States
Pfizer Investigational Site
Anaheim, California, United States
Pfizer Investigational Site
Bonita, California, United States
Pfizer Investigational Site
Fallbrook, California, United States
Pfizer Investigational Site
Hacienda Heights, California, United States
Pfizer Investigational Site
La Mesa, California, United States
Pfizer Investigational Site
Oceanside, California, United States
Start Date
August 1, 2006
Completion Date
January 1, 2007
Last Updated
February 2, 2021
NCT03338764
NCT00163046
NCT00666770
NCT04396327
NCT03331042
NCT00594022
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions